OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:OGXI
- CUSIP: 68230A10
- Web: www.oncogenex.com
- Market Cap: $9.98 million
- Outstanding Shares: 30,087,000
- 50 Day Moving Avg: $0.36
- 200 Day Moving Avg: $0.47
- 52 Week Range: $0.33 - $1.06
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
- Annual Revenue: $2.12 million
- Price / Sales: 4.81
- Book Value: $0.53 per share
- Price / Book: 0.64
- EBIDTA: ($17,880,000.00)
- Return on Equity: -89.62%
- Return on Assets: -63.95%
- Current Ratio: 8.81%
- Quick Ratio: 8.81%
- Average Volume: 151,617 shs.
- Beta: 2.02
- Short Ratio: 4.79
Frequently Asked Questions for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
What is OncoGenex Pharmaceuticals' stock symbol?
OncoGenex Pharmaceuticals trades on the NASDAQ under the ticker symbol "OGXI."
How were OncoGenex Pharmaceuticals' earnings last quarter?
OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.18. View OncoGenex Pharmaceuticals' Earnings History.
Are investors shorting OncoGenex Pharmaceuticals?
OncoGenex Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 760,164 shares, a decrease of 2.7% from the April 28th total of 781,243 shares. Based on an average trading volume of 136,735 shares, the short-interest ratio is presently 5.6 days.
Who are some of OncoGenex Pharmaceuticals' key competitors?
Some companies that are related to OncoGenex Pharmaceuticals include Novogen Limited (NVGN), Metabolix (YTEN), AEterna Zentaris (AEZS), Roka Bioscience (ROKA), RXi Pharmaceuticals Corporation (RXII), Jaguar Animal Health (JAGX), Ixico Plc (IXI), Synairgen plc (SNG), Ampliphi Biosciences Corp (APHB), Rosetta Genomics (ROSG), Anacor Pharmaceuticals (ANAC), Celator Pharmaceuticals (CPXX), Covance (CVD), ImmunoCellular Therapeutics Ltd (IMUC), Organovo Holdings (ONVO), Pharmacyclics (PCYC) and Synageva Biopharma Corp (GEVA).
Who are OncoGenex Pharmaceuticals' key executives?
OncoGenex Pharmaceuticals' management team includes the folowing people:
- Jack Goldstein Ph.D., Independent Chairman of the Board
- Scott Daniel Cormack, President, Chief Executive Officer, Treasurer, Secretary, Director
- John A. Bencich, Chief Financial Officer, Vice President
- Cindy Jacobs M.D., Ph.D., Executive Vice President, Chief Medical Officer
- Neil James Clendeninn M.D., Ph.D., Independent Director
- Martin A. Mattingly Ph.D., Independent Director
- H. Stewart Parker, Independent Director
- David V. Smith, Independent Director
Who owns OncoGenex Pharmaceuticals stock?
OncoGenex Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.39%) and Vanguard Group Inc. (2.24%). Company insiders that own OncoGenex Pharmaceuticals stock include Cindy Jacobs, John Bencich and Scott Daniel Cormack. View Institutional Ownership Trends for OncoGenex Pharmaceuticals.
Who sold OncoGenex Pharmaceuticals stock? Who is selling OncoGenex Pharmaceuticals stock?
Who bought OncoGenex Pharmaceuticals stock? Who is buying OncoGenex Pharmaceuticals stock?
How do I buy OncoGenex Pharmaceuticals stock?
Shares of OncoGenex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoGenex Pharmaceuticals' stock price today?
MarketBeat Community Rating for OncoGenex Pharmaceuticals (NASDAQ OGXI)MarketBeat's community ratings are surveys of what our community members think about OncoGenex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of OncoGenex Pharmaceuticals stock can currently be purchased for approximately $0.34.
Earnings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)Earnings History by Quarter for OncoGenex Pharmaceuticals (NASDAQ OGXI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/4/2016||Q216||($0.22)||($0.23)||$1.17 million||$2.10 million||View||N/A|
|5/12/2016||Q116||($0.12)||($0.12)||$4.09 million||$2.90 million||View||Listen|
|3/9/2016||Q4||($0.15)||($0.06)||$6.00 million||$6.02 million||View||N/A|
|11/12/2015||Q3||($0.17)||($0.16)||$5.97 million||$6.74 million||View||Listen|
|8/13/2015||Q2||$0.34||($0.26)||$16.10 million||$4.03 million||View||Listen|
|5/14/2015||Q115||($0.34)||($0.20)||$4.66 million||$1.40 million||View||Listen|
|3/26/2015||Q414||($0.30)||($0.27)||$4.30 million||$5.70 million||View||N/A|
|10/30/2014||($0.38)||($0.23)||$4.69 million||$4.80 million||View||N/A|
|8/7/2014||($0.55)||($0.47)||$11.73 million||$4.93 million||View||N/A|
|4/30/2014||($0.50)||($0.59)||$8.68 million||$11.73 million||View||N/A|
|3/11/2014||Q113||($0.66)||($0.45)||$10.20 million||$8.60 million||View||N/A|
|11/8/2012||Q312||($0.49)||($0.40)||$4.52 million||$6.57 million||View||N/A|
Earnings Estimates for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Insider Ownership Percentage: 3.30%Insider Trades by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Institutional Ownership Percentage: 13.95%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/19/2016||John Bencich||CFO||Sell||1,380||$0.57||$786.60|| |
|6/13/2016||Cindy Jacobs||CMO||Sell||1,437||$1.03||$1,480.11|| |
|6/13/2016||Scott Daniel Cormack||CEO||Sell||4,856||$1.03||$5,001.68|| |
|3/15/2016||Cindy Jacobs||CMO||Sell||3,254||$0.83||$2,700.82|| |
|3/15/2016||John Bencich||CFO||Sell||834||$0.83||$692.22|| |
|3/15/2016||Scott Daniel Cormack||CEO||Sell||12,033||$0.83||$9,987.39|| |
|8/18/2015||John Bencich||CFO||Sell||1,427||$2.76||$3,938.52|| |
|6/12/2015||Cindy Jacobs||CMO||Sell||1,408||$2.69||$3,787.52|| |
|6/12/2015||Scott Daniel Cormack||CEO||Sell||4,571||$2.69||$12,295.99|| |
|5/20/2015||Cindy Jacobs||CMO||Sell||2,092||$1.88||$3,932.96|| |
|5/20/2015||Scott Daniel Cormack||CEO||Sell||7,543||$1.88||$14,180.84|| |
|8/13/2014||Cindy Jacobs||CMO||Sell||5,650||$3.17||$17,910.50|| |
|8/13/2014||Scott Daniel Cormack||CEO||Sell||18,341||$3.17||$58,140.97|| |
|3/17/2014||Cindy Jacobs||CMO||Sell||1,250||$12.25||$15,312.50|| |
|3/17/2014||Scott Daniel Cormack||CEO||Sell||4,634||$12.25||$56,766.50|| |
|8/19/2013||Cindy Jacobs||CMO||Sell||1,364||$8.68||$11,839.52|| |
|8/19/2013||Scott Daniel Cormack||CEO||Sell||3,112||$8.68||$27,012.16|| |
|3/12/2013||Scott Daniel Cormack||CEO||Sell||2,134||$11.90||$25,394.60|| |
|8/15/2012||Jack Goldstein||Director||Buy||1,000||$14.38||$14,380.00|| |
Headline Trends for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Latest Headlines for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
|Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared ... - PR Newswire (press release)|
www.prnewswire.com - June 14 at 12:11 AM
|Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC|
finance.yahoo.com - June 13 at 7:09 PM
|OncoGenex Pharmaceuticals Inc (OGXI) Sees Significant Decline in Short Interest|
www.americanbankingnews.com - June 2 at 9:14 AM
|OncoGenex Pharmaceuticals Inc (OGXI) Posts Earnings Results, Beats Expectations By $0.18 EPS|
www.americanbankingnews.com - May 16 at 5:28 PM
|OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2017|
finance.yahoo.com - May 15 at 10:02 AM
|OncoGenex to Report First Quarter 2017 Financial Results on May 15, 2017|
finance.yahoo.com - May 9 at 11:20 AM
|SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Oncogenex Pharmaceuticals ... - PR Newswire (press release)|
www.prnewswire.com - May 6 at 12:18 AM
|SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Oncogenex Pharmaceuticals, Inc. - OGXI|
finance.yahoo.com - May 5 at 7:15 PM
|Research Reports Coverage on Biotech Stocks -- Novan, Stemline Therapeutics, BioDelivery Sciences, and OncoGenex Pharma|
www.bizjournals.com - April 25 at 10:30 AM
|ETFs with exposure to OncoGenex Pharmaceuticals, Inc. : April 19, 2017|
finance.yahoo.com - April 19 at 7:01 PM
|ETFs with exposure to OncoGenex Pharmaceuticals, Inc. : April 5, 2017|
finance.yahoo.com - April 7 at 11:42 AM
|Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma|
www.prnewswire.com - March 24 at 8:38 AM
|Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society …|
finance.yahoo.com - March 8 at 9:20 AM
|Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")|
finance.yahoo.com - March 8 at 9:20 AM
|ONCOGENEX PHARMACEUTICALS, INC. Financials|
finance.yahoo.com - March 1 at 7:13 PM
|Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National …|
finance.yahoo.com - March 1 at 10:23 AM
|ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul|
us.rd.yahoo.com - March 1 at 10:23 AM
|Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National Institutes of Health to Advance the Development of Cytisine for Smoking Cessation|
us.rd.yahoo.com - March 1 at 10:23 AM
|Q4 2016 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close|
us.rd.yahoo.com - February 23 at 9:21 AM
|OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016|
finance.yahoo.com - February 23 at 9:21 AM
|ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen|
biz.yahoo.com - February 23 at 9:21 AM
|OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium|
us.rd.yahoo.com - February 22 at 7:05 PM
|9:01 am OncoGenex Pharma announces that apatorsen results from two randomized Phase 2 clinical trials were presented at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium; Clinical data from trials in bladder and|
us.rd.yahoo.com - February 22 at 7:05 PM
|OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the ... - Yahoo Finance|
finance.yahoo.com - February 21 at 5:51 PM
|OncoGenex to Report Year End 2016 Financial Results on Feb. 23, 2017|
finance.yahoo.com - February 16 at 6:34 PM
|After reverse takeover, Bothell's OncoGenex changes name, focuses on smoking cessation drug|
www.bizjournals.com - January 17 at 7:23 PM
|OncoGenex Pharma (OGXI) to Merge with Achieve Life Science - StreetInsider.com|
www.streetinsider.com - January 6 at 7:44 PM
|ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - January 6 at 7:44 PM
OncoGenex Pharmaceuticals (OGXI) Chart for Thursday, June, 22, 2017